The drug is administered intravenously or intramuscularly.
Parenteral administration of piracetam is given when oral administration of the drug is not possible (tablets, capsules, oral solution), for example, if swallowing is difficult or when the patient is in a coma, with intravenous administration being preferred.
If there is an opportunity, they switch to oral administration of the drug (see the instructions for the medical use of the respective forms of the drug release).
Intravenous infusion of the daily dose is performed through a catheter at a constant rate for 24 hours a day (for example, coma or at the initial stage of treatment with severe myoclonia). Preliminary preparation is diluted in one of the compatible infusion solutions: dextrose 5%, 10% or 20%, fructose 5%, 10% or 20%, sodium chloride 0.9%, dextran 40 (10% in sodium chloride solution 0.9% ), Ringer, mannitol 20%.The total volume of solution intended for administration is determined taking into account the clinical indications and the patient's condition.
Bolus intravenous administration (for example, with the withdrawal of withdrawal syndrome with alcoholism, emergency treatment of sickle cell anemia, etc.) is performed for at least 2 minutes, the daily dose is then divided into several injections (2-4) at regular intervals so , so that the dose per injection does not exceed 3 g. Intramuscularly the drug is administered if the introduction through the vein is difficult or the patient is overexcited. However, the amount of the drug that can be administered intramuscularly is limited, especially in children and patients with a reduced body weight. In addition, the administration of the drug intramuscularly can be painful because of the large volume of fluid. The volume of the solution administered intramuscularly can not exceed 5 ml. The frequency of administration of the drug is similar to that of its intravenous or oral administration.
The duration of treatment is determined by the doctor depending on the disease and taking into account the dynamics of the symptoms.
Symptomatic treatment of chronic psychoorganic syndrome. 2.4-4.8 g.
Treatment of cerebrovascular disorders (stroke). 4.8-12 g / day.
Treatment of coma, as well as the difficulties of perception in people with brain trauma. The initial dose is 9-12 g / day, supporting - 2 g / day. Treatment lasts no less than 3 weeks.
Alcohol withdrawal syndrome. 12 g / day. Supportive dose of 2.4 g / day.
Treatment of dizziness and related disorders of balance. 2,4-4,8 g per day.
Cortical myoclonus. Treatment begins with a dose of 7.2 g / day, every 3-4 days the dose is increased by 4.8 g / day until the maximum dose of 24 g / day is reached. Treatment continues throughout the period of the disease. Every 6 months, attempts should be made to reduce the dose or discontinue the drug, gradually reducing the dose by 1.2 g / day every 2 days. In the absence of effect or a slight therapeutic effect, treatment is discontinued.
Sickle cell anemia. The daily preventive dose is 160 mg / kg of body weight divided into four equal doses. During the crisis - 300 mg / kg intravenously, divided into four equal doses.
Dosing to patients with impaired renal function.
Because the piracetam is excreted from the body by the kidneys, caution should be exercised in the treatment of patients with renal insufficiency and appropriate dosage in accordance with this dosing regimen.
| Renal failure | Clearance creatinine (ml / min) | Dosing |
| Norm | >80 | Usual Dose |
| Lightweight | 50-79 | 2/3 of the usual dose in 2-3 doses |
| Average | 30-49 | 1/3 of the usual dose in 2 divided doses |
| Heavy | <30 | 1/6 of the usual dose, once |
| The final stage | - | contraindicated |
Elderly, the dose is corrected in the presence of renal failure, with prolonged therapy requires monitoring of the functional state of the kidneys.
Dosing to patients with impaired liver function
Patients with a dysfunction of the liver do not need a dose adjustment. Patients with impaired functions and kidneys and liver dosing is carried out according to the scheme (see the section "Dosing to patients with impaired renal function").